Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a mixed set of valuation checks mean the current price is not an obvious bargain or clear bubble. With fresh product news and shifting expectations around its portfolio, investors are weighing whether the recent rebound leaves enough room for attractive long term returns.
The share price is down about 28% over five years. This points to a company that has yet to fully reward long term holders despite a stronger showing in the last year.
Progress on Pfizer and Valneva's Lyme disease vaccine candidate can support confidence in future cash flows, while legal and product related risks such as the Chantix settlement may limit how much of a premium the market is willing to put on the stock.
The broader checks give Pfizer a mixed read on value, with the company scoring 3 out of 6 on Simply Wall St's valuation framework, so it does not stand out as clearly cheap or clearly expensive.
The issue now is whether the current price for Pfizer properly reflects that mixed valuation picture or pushes the stock too far in either direction.
Find out why Pfizer's 14.0% return over the last year is lagging behind its peers.
The P/E ratio is a useful way to look at Pfizer because earnings are still the main anchor for how investors value this large pharmaceutical business. Pfizer currently trades on a P/E of 35.2x, which is more than double the pharmaceuticals industry average of 16.9x and also below the peer group average of 52.5x. That places the stock at a premium to the broader sector, even if it does not sit at the very top of the peer range.
Simply Wall St's fair P/E for Pfizer, which adjusts for its specific growth outlook, margins, size and risk profile, is 24.6x. The current 35.2x multiple is therefore meaningfully higher than this tailored estimate. Despite the recent Lyme disease vaccine progress and stronger non Covid revenue mix, the P/E still indicates investors are paying a higher valuation for Pfizer shares relative to what this framework suggests is justified.
On this P/E yardstick, Pfizer stock appears overvalued.
See what the numbers say about this price — find out in our valuation breakdown.
Simply Wall St Narratives pick up where Pfizer's valuation puzzle leaves off and spell out which combinations of future growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than today's price. Rather than focus on a single multiple or model output, each narrative lays out the assumptions behind its view of fair value so you can compare those expectations with Pfizer's reported results over time.
Community views on Pfizer sit on opposite sides of the fence, with one camp leaning into the pipeline story and the other focused on pressure from pricing and patents.
"Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions, stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages..."
Read the full Bull Case to see why Pfizer could be undervalued
"Pfizer faces intensifying global pressure to contain healthcare costs, as governments and insurers negotiate aggressively for lower drug prices and plan to institute price caps, these changes will directly squeeze top-line revenue growth and compress net margins in Pfizer's largest markets..."
Read the full Bear Case to see why Pfizer could be overvalued
Do you think there's more to the story for Pfizer? Head over to our Community to see what others are saying!
Pfizer looks overvalued on current market multiples, which suggests the recent optimism already prices in a fair amount of good news. With broader valuation checks sitting in a mixed range, the stock does not screen as a clear bargain or an obvious bubble. The key question from here is whether Pfizer can deliver enough durable earnings growth from its pipeline to make the current premium feel routine rather than stretched, especially in the face of pricing and legal pressures highlighted by recent events.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PFE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]